IAG’s scientific team will present our 5 abstracts and 1 publication in inflammatory arthritis, osteoarthritis, degenerative and genetic muscle diseases, scleroderma, rare musculoskeletal diseases, including some that are based on machine learning and AI concepts.
Given the increasing need for collaboration in therapy development, Dr. Kubassova and Dr. Roettger will introduce IAG’s technology-enabled, risk-sharing and mitigation partnerships, and targeted development strategies.
Dr. Kubassova will discuss the challenges biotechnology companies face in the industry and will explain IAG’s unique approach to solving these problems.
Following Successful Completion of LANTERN-1 Clinical Trial.
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to treat the first indication in the company’s pipeline, MPS I (Mucopolysaccharidosis type I).
